BPC-157

Body Protection Compound 157

Grade C: Preliminary or limited human evidence

TL;DR: Human evidence for BPC-157 is limited to a small number of uncontrolled pilot studies from a single research group; no randomized controlled trial has been completed or published. These pilots involved very few participants, lacked placebo controls, and are insufficient to establish efficacy in any indication. The preponderance of published mechanistic and efficacy data comes from animal models, primarily rodents, where BPC-157 has been studied for tissue repair, gut healing, tendon regeneration, and neurological effects. The animal literature is extensive but does not substitute for controlled human trials. Until adequately powered, placebo-controlled human trials are conducted, BPC-157's efficacy in humans remains unestablished.

Key Takeaways

Grade C: Preliminary or limited human evidence
Not FDA approved: Not FDA-approved; compounding status subject to ongoing regulatory review.
Compounding: The nomination to add BPC-157 to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.

BPC-157 chemical structure — Structure via PubChem CID 9941957

Mechanism

Proposed to modulate growth factor signaling and angiogenesis via FAK-paxillin and NO-synthase pathways, promoting tissue repair and cytoprotection, though the precise human mechanism is not established.

Evidence

Human evidence for BPC-157 is limited to a small number of uncontrolled pilot studies from a single research group; no randomized controlled trial has been completed or published. These pilots involved very few participants, lacked placebo controls, and are insufficient to establish efficacy in any indication. The preponderance of published mechanistic and efficacy data comes from animal models, primarily rodents, where BPC-157 has been studied for tissue repair, gut healing, tendon regeneration, and neurological effects. The animal literature is extensive but does not substitute for controlled human trials. Until adequately powered, placebo-controlled human trials are conducted, BPC-157's efficacy in humans remains unestablished.

Safety and risks

Human safety data is limited to the same small uncontrolled pilot studies that form the efficacy base; these reports noted no adverse events but enrolled too few participants to reliably detect uncommon or delayed harms. Long-term human safety data do not exist. A theoretical concern involves interference with angiogenic signaling pathways; in individuals with or at elevated risk for malignancy, the implications of sustained angiogenic modulation are unknown and have not been studied in humans. Compounded formulations are not subject to FDA manufacturing quality oversight. Purity and dosing consistency of commercially available preparations are unverified.

Interactions

No human pharmacokinetic or drug-interaction data exist. Theoretical caution is warranted with anticoagulants and angiogenesis-affecting agents given proposed mechanism.

Federal compounding status

Nomination withdrawn (was Category 2) as of 2026-06-02.

This substance was nominated for the FDA 503A or 503B bulk-substances list and previously sat in the Category 2 (significant safety risk) group; the nomination was later withdrawn, so it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding. FDA source

Federal status only, from public FDA records. State pharmacy-board rules vary and are not covered here. This is regulatory reporting, not legal advice. All compounds.

Compounding legality

The nomination to add BPC-157 to the FDA 503A or 503B bulk-substances list was withdrawn; it is not on an active FDA bulks list and is not eligible for routine pharmacy compounding.

Sources

BPC-157 is Not FDA approved. PeptideGrids presents evidence and regulatory status for informational purposes only. We do not sell, supply, source, or help anyone obtain this compound, and we provide no dosing or administration guidance. This is not medical advice; consult a licensed clinician. Full disclaimer.

Last reviewed June 2, 2026 by PeptideGrids editorial team (independently audited).